183 related articles for article (PubMed ID: 29965902)
1. Medical Management of Glaucoma in Exfoliation Syndrome.
Michalik AZ; Kaufman PL
J Glaucoma; 2018 Jul; 27 Suppl 1():S87-S90. PubMed ID: 29965902
[TBL] [Abstract][Full Text] [Related]
2. Medical therapy for glaucoma: what to add after a prostaglandin analogs?
Tanna AP; Lin AB
Curr Opin Ophthalmol; 2015 Mar; 26(2):116-20. PubMed ID: 25594765
[TBL] [Abstract][Full Text] [Related]
3. Glaucoma medical treatment: philosophy, principles and practice.
Migdal C
Eye (Lond); 2000 Jun; 14 ( Pt 3B)():515-8. PubMed ID: 11026981
[TBL] [Abstract][Full Text] [Related]
4. Carbonic anhydrase inhibitors as fourth drug in primary glaucomas: Is it worth it?
Juncal VR; Abdo Jorge F; Paranhos A; Santos Prata T
Can J Ophthalmol; 2015 Aug; 50(4):297-301. PubMed ID: 26257224
[TBL] [Abstract][Full Text] [Related]
5. Association of ocular hypotensive medication types with dynamic contour tonometry and Goldmann applanation tonometry measurements in a glaucoma and ocular hypertensive population.
Tzamalis A; Kynigopoulos M; Chalvatzis N; Dimitrakos S; Schlote T
J Ocul Pharmacol Ther; 2013 Feb; 29(1):41-7. PubMed ID: 23066787
[TBL] [Abstract][Full Text] [Related]
6. Twenty-four hour control of intraocular pressure with dorzolamide and timolol maleate in exfoliation and primary open-angle glaucoma.
Konstas AG; Maltezos A; Bufidis T; Hudgins AG; Stewart WC
Eye (Lond); 2000 Feb; 14 ( Pt 1)():73-7. PubMed ID: 10755105
[TBL] [Abstract][Full Text] [Related]
7. Update on the Medical Treatment of Primary Open-Angle Glaucoma.
Cheema A; Chang RT; Shrivastava A; Singh K
Asia Pac J Ophthalmol (Phila); 2016; 5(1):51-8. PubMed ID: 26886120
[TBL] [Abstract][Full Text] [Related]
8. Review of the influence of pigment dispersion and exfoliation glaucoma diagnosis on intraocular pressure in clinical trials evaluating primary open-angle glaucoma and ocular hypertension.
Stewart WC; DeMill DL; Wirostko BM; Nelson LA; Stewart JA
J Glaucoma; 2013 Aug; 22(6):506-9. PubMed ID: 22274674
[TBL] [Abstract][Full Text] [Related]
9. Central corneal thickness and measured IOP response to topical ocular hypotensive medication in the Ocular Hypertension Treatment Study.
Shimmyo M
Am J Ophthalmol; 2005 Jun; 139(6):1148; author reply 1148-9. PubMed ID: 15953471
[No Abstract] [Full Text] [Related]
10. [Innovative glaucoma therapy. Glaucoma therapy with topical carbonic anhydrase inhibitors].
Herkel U; Pfeiffer N
Ophthalmologe; 2001 Oct; 98(10):929-33. PubMed ID: 11699313
[TBL] [Abstract][Full Text] [Related]
11. Intraocular pressure-lowering medications and long-term outcomes of selective laser trabeculoplasty.
Woo DM; Healey PR; Graham SL; Goldberg I
Clin Exp Ophthalmol; 2015; 43(4):320-7. PubMed ID: 25287743
[TBL] [Abstract][Full Text] [Related]
12. Reproducibility of the water-drinking test in patients with exfoliation syndrome and exfoliative glaucoma.
Özyol E; Özyol P; Karalezli A
Acta Ophthalmol; 2016 Dec; 94(8):e795-e798. PubMed ID: 27316559
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of intraocular pressure-lowering medication determined by washout.
Jampel HD; Chon BH; Stamper R; Packer M; Han Y; Nguyen QH; Ianchulev T
JAMA Ophthalmol; 2014 Apr; 132(4):390-5. PubMed ID: 24481483
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the efficacy and safety of latanoprost 0.005% compared to brimonidine 0.2% or dorzolamide 2% when added to a topical beta-adrenergic blocker in patients with primary open-angle glaucoma or ocular hypertension.
Stewart WC; Sharpe ED; Day DG; Kolker AE; Konstas AG; Lee WH; Rieser JC; Chopra H; Holmes KT
J Ocul Pharmacol Ther; 2000 Jun; 16(3):251-9. PubMed ID: 10872922
[TBL] [Abstract][Full Text] [Related]
15. The comparative ocular hypotensive effect of apraclonidine with timolol maleate in exfoliation versus primary open-angle glaucoma patients.
Konstas AG; Maltezos A; Mantziris DA; Sine CS; Stewart WC
Eye (Lond); 1999 Jun; 13 ( Pt 3a)():314-8. PubMed ID: 10624424
[TBL] [Abstract][Full Text] [Related]
16. Effect of laser trabeculoplasty on nocturnal intraocular pressure in medically treated glaucoma patients.
Lee AC; Mosaed S; Weinreb RN; Kripke DF; Liu JH
Ophthalmology; 2007 Apr; 114(4):666-70. PubMed ID: 17188360
[TBL] [Abstract][Full Text] [Related]
17. The influence of glaucoma medications on ocular surface disease in primary open-angle glaucoma patients with and without conjunctivochalasis.
Kocabeyoglu S; Mocan MC; Irkec M
Acta Ophthalmol; 2014 Nov; 92(7):e592-3. PubMed ID: 24774884
[No Abstract] [Full Text] [Related]
18. Studies of monocular trials of glaucoma medications: conflicting results explained by varying methods.
Leffler CT
Arch Ophthalmol; 2009 May; 127(5):707-8; author reply 708. PubMed ID: 19433731
[No Abstract] [Full Text] [Related]
19. Pharmacological management of primary open-angle glaucoma: second-line options and beyond.
Webers CA; Beckers HJ; Nuijts RM; Schouten JS
Drugs Aging; 2008; 25(9):729-59. PubMed ID: 18729546
[TBL] [Abstract][Full Text] [Related]
20. Effects of antiglaucoma drugs on blood flow of optic nerve heads and related structures.
Mayama C; Araie M
Jpn J Ophthalmol; 2013 Mar; 57(2):133-49. PubMed ID: 23321913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
